The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...
The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...
The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...
Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...
Bullish option flow detected in Novavax (NVAX) with 12,673 calls trading, 2x expected, and implied vol increasing almost 14 points to 90.76%.
Shares of Novavax Inc. NVAX slid 6.35% to $5.60 Thursday, on what proved to be an all-around dismal trading session for the ...
The FDA was scheduled to release its decision on Novavax’s updated, protein-based COVID-19 vaccine on April 1.
Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “Novavax can confirm that April 1, 2025, was the ...
Novavax (NasdaqGS:NVAX) recently experienced a significant decline of 21% over the past week, coinciding with leadership changes, including the retirement of longtime Chairman James Young and the ...
The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...
The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...